Archimedes Pharma Ltd., a leading international specialty pharma company, today announced that the European Commission has granted marketing authorisation for its lead product, PecFent*, an innovative fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

Portola Pharmaceuticals, Inc. today announced results from the Phase 2 INNOVATE-PCI study of its investigational antiplatelet drug, elinogrel, the only competitive, reversible direct-acting P2Y12 ADP receptor antagonist.

Gene testing is shaping up to be a marketing battleground for new blood thinners like AstraZeneca's Brilinta, underscoring the power and limitations of genetics as a tool to predict medical outcomes.

The arrival of generic copies of Sanofi-Aventis and Bristol-Myers Squibb's top-seller Plavix makes the issue a hot topic scientifically and commercially, new studies at the European Society of Cardiology congress on Sunday showed.

French drugmaker Sanofi-Aventis (SASY.PA) said it would continue a legal battle in the United States against a generic version of its blood clot preventer Lovenox, despite a court rebuff.

Indianapolis-based Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, has won a court order extending the ban on generic versions of the attention-deficit treatment Strattera while it appeals a patent ruling.

The US Food and Drug Administration (FDA) approved Tekamlo (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine.

Inspire Pharmaceuticals, Inc. /quotes/comstock/15*!isph/quotes/nls/isph (ISPH 4.56, +0.07, +1.56%) announced today it has entered into an Amended and Restated License,

U.S.-based generic drug maker Alvogen Inc is mulling the acquisition of a government stake in Bosnia's top drug firm Bosnalijek BSNL.SJ as a step to becoming a leading drug company in the region.